A promising clinical trial for a broad-spectrum antiviral drug called NV-CoV-2 is currently underway, according to NanoViricides. As a global leader in the development of highly effective antiviral therapies, NanoViricides is focused on addressing unmet medical needs through their novel nanomedicines platform.
NV-CoV-2, the company’s lead drug candidate, is being tested in Phase 1a/1b Safety and Preliminary Efficacy Human Clinical Trials. The trials are being conducted by Karveer Meditech Pvt. Ltd., NanoViricides’ licensee and co-developer in India.
The Phase 1a trial is progressing rapidly. It involves evaluating the safety and tolerability of NV-CoV-2 in healthy individuals through the administration of either an oral syrup or oral gummies. The trial will proceed to Phase 1b if no serious adverse events occur during Phase 1a.
Enrollment for the highest single dose level of NV-CoV-2 oral syrup (40mg/Kg) and oral gummy (2,000mg) has already begun. The lower and middle dose cohorts have already completed their respective treatments, with no adverse events reported at any dosage level.
Phase 1b is expected to commence shortly. In this phase, multiple doses of NV-CoV-2 oral syrup and oral gummies will be administered to healthy individuals to further assess safety and tolerability. Additionally, patients with mild to moderate/severe COVID-19 will be enrolled in separate cohorts to evaluate the drug’s efficacy. Patients requiring hospitalization within 48 hours of screening will be excluded from this phase.
Anil R. Diwan, Ph.D., President and Executive Chairman of NanoViricides, expressed satisfaction with the trial’s progress, stating, This clinical trial we believe will be a springboard for NV-CoV-2 to launch into multiple antiviral indications in the near future. NV-387 is designed as a bio-mimetic that can possibly be an effective drug against many viruses including the coronaviruses. If successful, it is poised to satisfy many as yet unmet medical needs for the global population, not just limited to COVID.
NanoViricides’ NV-CoV-2 shows great promise in addressing the urgent need for effective treatments against the coronavirus. The ongoing clinical trial aims to establish the drug’s safety, tolerability, and potential efficacy in treating COVID-19 and potentially other viral infections. The company’s innovative nanomedicines platform has positioned them as a frontrunner in the development of antiviral therapies, providing hope for millions of people worldwide.
